Keros Therapeutics (KROS) Stock: Buy, Sell, or Hold?
KROS - Keros Therapeutics, Inc. Common Stock
$11.35
0.17 (1.52%)
▲
5d:
+2.25%
30d:
-2.41%
90d:
+12.82%
BUY
MODERATE Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 04, 2026
11d
Get Alerted When KROS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: KROS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: KROS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: KROS is currently trading at $11.35, which is considered fair relative to its 30-day fair value range of $11.04 to $11.59.
Technical Outlook: Technically, KROS is in a uptrend. Immediate support is located at $10.63, while resistance sits at $12.26.
Market Sentiment: KROS scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $19.83 (+74.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KROS is in a uptrend. Immediate support is located at $10.63, while resistance sits at $12.26.
Market Sentiment: KROS scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $19.83 (+74.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$11.04 -
$11.59
Company Quality Score
58/100
(HOLD)
Options IV Signal
55th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Options fairly priced (IV 55th percentile)
- BULLISH: Strong technical setup (65/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 74.7% below Wall St target ($19.83)
- BULLISH: Bottoming setup score 65/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$11.04 -
$11.59
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$2.31
(20.4%)
Support & Resistance Levels
Support Level
$10.63
Resistance Level
$12.26
Current Trend
Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.72
Wall Street Target
$19.83
(+74.7%)
Revenue Growth (YoY)
-99.8%
Share & Embed Analysis
Last updated: October 23, 2026 12:22 AM ET
Data refreshes hourly during market hours. Next update: 1:22 AM
Data refreshes hourly during market hours. Next update: 1:22 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KROS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
PRAX
Praxis Precision Medicin… |
STRONG BUY
20 analysts |
$650 | 61 BUY |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
17 analysts |
$36 | 57 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
STRONG BUY
20 analysts |
$31 | 66 BUY |
|
ELVN
Enliven Therapeutics Inc. |
STRONG BUY
14 analysts |
$74 | 60 BUY |
|
IMUX
Immunic Inc |
STRONG BUY
12 analysts |
$43 | 68 BUY |
Advanced KROS Option Strategies
Professional options setups generated by AI based on today's KROS price and gamma walls.
